Sotatercept for PAH imaging study
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called sotatercept to see if it improves heart and lung blood vessel health in people with PAH. Participants will have special PET scans to measure changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a specific type of pulmonary arterial hypertension (PAH) confirmed by a heart catheterization within the last 12 months, with high pressure in the lung arteries but normal pressure on the left side of the heart.
- You are already taking two or three PAH medicines (background therapy).
- Your PAH symptoms limit you some with activities (WHO functional class II or III).
- You are not pregnant or breastfeeding, and your kidney and liver function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.